Technology

SPHERE AX Partners with U.S. AI Semiconductor Company Blaize at the National Assembly

Published

8 hours ago

June 24, 2026

Korea-U.S. Physical AI Cooperation Gets Underway — Joint Development of AI Semiconductor-Based Products

EL DORADO HILLS, Calif. and SEOUL, South Korea, June 24, 2026 /PRNewswire/ — SPHERE AX (CEO: Yunha Park), a company specializing in Vision AI and Edge AI Computing, announced that it signed a strategic memorandum of understanding (MOU) with Blaize Holdings, Inc. (Nasdaq: BZAI, Nasdaq: BZAIW) (“Blaize”), a global AI semiconductor company based in El Dorado Hills, California, U.S.A., and will pursue joint development and commercialization of AI semiconductor-based products, aiming to establish a leading position in the global Physical AI market.

The signing ceremony was held prior to the “Policy Roundtable for Korea-U.S. Physical AI Cooperation and the Creation of an AI Industry Innovation Ecosystem” at the National Assembly. The ceremony coincided with ongoing discussions regarding strengthening the national competitiveness of the AI semiconductor industry and expanding global technology cooperation.

Through this cooperation, the two companies intend to explore a collaborative framework across a wide range of areas, including joint research and development in Edge AI Computing, potential commercialization of AI semiconductor-based solutions, business development opportunities across target industries, and joint business development for domestic and overseas customers.

In particular, this cooperation is significant because, through it, the parties intend to build a Korea-based AI product connecting overseas core semiconductor technology with domestic productization for global supply.

Together, Blaize and SPHERE AX plan to develop a next-generation physical AI solution targeted at the global market by combining Blaize’s AI semiconductor technology, optimized for physical AI, with SPHERE AX’s core software expertise, including its vision AI. The jointly developed solution is expected to be applied across various sectors, including smart cities, smart factories, industrial safety, security, robotics, and mobility, making a meaningful step in Korea-U.S. cooperation in the physical AI sector.

Beginning with this strategic partnership, the partners intend to work toward establishing an AI semiconductor-based product development and production system in Korea and actively contribute to strengthening Korea’s AI industry competitiveness and expand the global supply chain by linking their efforts with the government’s AI semiconductor industry promotion policies and Korea’s advanced manufacturing industries. Through its engagement with SPHERE AX, Blaize recognized the company’s technology capabilities and growth potential in the Korean market, and both companies intend to build their collaboration over the long term.

Yunha Park, CEO of SPHERE AX, stated, “This cooperation will be more than a simple technology alliance. It will be the first step toward developing and producing actual commercial AI products in Korea based on globally competitive AI semiconductor technology.” Yunha added, “We will continue to expand various global businesses so that Korea can grow into a key production hub in the global Edge AI market.”

Dinakar Munagala, CEO of Blaize, stated, “Korea is a strategically important market, combining global technology leadership with the speed to bring new AI solutions to market.” Munagala added, “Through our partnership with SPHERE AX, we’ll create new growth opportunities and expand the reach of our platform from Asia into the global market.”

Company Introductions

SPHERE AX

A company specializing in Vision AI and Edge AI Computing, SPHERE AX provides solutions in the fields of Automotive, Robotics, Smart Factory, and Industrial Safety AI based on its proprietary AI video analytics technology.

Blaize

Blaize Holdings, Inc. (Nasdaq: BZAI, Nasdaq: BZAIW) (“Blaize”), is an AI semiconductor company headquartered in El Dorado Hills, California, with a global presence. The company delivers a programmable AI platform purpose-built for AI inference in real-world environments. Its Hybrid AI architecture combines the proprietary Blaize GSP (Graph Streaming Processor) with GPU-based infrastructure, enabling AI workloads to run across edge, cloud, and data center. Blaize’s solutions support computer vision, multimodal AI, and sensor-driven applications across smart cities, industrial automation, telecommunications, retail, logistics, and mission critical.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are based on beliefs and assumptions and on information currently available to Blaize, including expectations and scope of the Memorandum of Understanding with Sphere AX, the potential value, investment in, and results of the engagement, the availability of integrated solutions, the industry in which Blaize operates, market opportunities, and product offerings. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to those factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 24, 2026, as amended by Amendment No.1 on Form 10-K/A filed with the SEC on April 30, 2026, our Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026, and other documents filed by Blaize from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Blaize assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law, including the securities laws of the United States and the rules and regulations of the SEC. Blaize does not give any assurance that it will achieve its expectations.

Blaize Contact
press@blaize.com
www.blaize.com

Investors
ir@blaize.com
www.blaize.com

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/sphere-ax-partners-with-us-ai-semiconductor-company-blaize-at-the-national-assembly-302809038.html

SOURCE Blaize Inc.

Technology

AI in Healthcare Market to Reach USD 505.6 Billion by 2033, Driven by Rapid Adoption of AI-Powered Clinical Solutions and Digital Healthcare Transformation

Published

7 minutes ago

June 24, 2026

Global AI in Healthcare Market Expected to Expand at 38.90% CAGR from 2026 to 2033 as Healthcare Systems Embrace Predictive Analytics, Precision Medicine, and Automation

SAN FRANCISCO, June 24, 2026 /PRNewswire/ — The global artificial intelligence (AI) in healthcare market is projected to witness significant growth, reaching USD 505.59 billion by 2033, according to a new report by Grand View Research, Inc. The market was estimated at USD 36.7 billion in 2025 and is anticipated to grow from USD 50.7 billion in 2026 to USD 505.6 billion by 2033, expanding at a compound annual growth rate (CAGR) of 38.90% during the forecast period from 2026 to 2033.

The increasing demand for advanced healthcare technologies, rising adoption of artificial intelligence-driven clinical decision support systems, growing healthcare data volumes, and the need for improved patient outcomes are accelerating the integration of AI across healthcare ecosystems. AI technologies are enabling healthcare providers to transition from traditional reactive models toward predictive, personalized, and preventive healthcare approaches.

AI Transforming Healthcare Delivery Through Advanced Analytics and Automation

Artificial intelligence is emerging as a transformative technology within the healthcare industry by enabling faster diagnosis, improved treatment planning, operational efficiency, and enhanced patient engagement. AI-powered solutions are being increasingly deployed across medical imaging, clinical decision support, drug discovery, patient monitoring, administrative automation, and personalized medicine applications.

Healthcare organizations are leveraging machine learning, natural language processing, computer vision, and deep learning technologies to analyze complex medical datasets, identify disease patterns, and support healthcare professionals with actionable insights. The ability of AI systems to process large-scale clinical information is helping improve diagnostic accuracy and optimize healthcare workflows.

Clinical decision support systems powered by AI are becoming increasingly important as healthcare providers seek real-time insights to enhance decision-making and improve patient care outcomes. These solutions assist physicians by analyzing patient information, identifying potential risks, and supporting evidence-based treatment strategies.

Get Free Sample of this Research Report for more latest industry insights

Rising Healthcare Data Volumes and Digital Transformation Fuel Market Growth

The rapid digitization of healthcare infrastructure is one of the major factors contributing to the expansion of the AI in healthcare market. The increasing adoption of electronic health records (EHRs), connected medical devices, wearable technologies, and remote patient monitoring solutions is generating substantial amounts of healthcare data.

AI platforms are helping organizations convert this data into meaningful clinical and operational intelligence. Healthcare providers are increasingly adopting AI solutions to improve resource utilization, streamline workflows, reduce operational costs, and deliver more personalized patient experiences.

The growing prevalence of chronic diseases, increasing healthcare expenditure, and rising demand for efficient healthcare delivery models are further supporting market growth. AI-driven solutions are enabling healthcare systems to improve early disease detection, enhance treatment outcomes, and support continuous patient monitoring.

Software Segment and AI-Based Solutions Drive Healthcare Innovation

The AI in healthcare market is segmented by component, application, technology, end use, and region. The market includes hardware, software, and services components, with AI software solutions playing a critical role in enabling advanced analytics, automation, and decision-support capabilities.

AI applications across clinical trials, cybersecurity, medical imaging analysis, robotic-assisted procedures, drug discovery, and healthcare management are expanding rapidly as organizations invest in intelligent healthcare infrastructure.

The integration of AI into clinical research is also creating new opportunities by improving patient recruitment, accelerating data analysis, and supporting faster development of medical innovations. AI technologies are helping pharmaceutical and biotechnology companies analyze complex biological data and enhance research efficiency.

Growing Adoption of AI in Precision Medicine and Personalized Healthcare

The increasing focus on personalized medicine is creating new growth opportunities for AI adoption in healthcare. AI algorithms can analyze patient-specific information, including medical history, genetic data, and clinical indicators, to support individualized treatment strategies.

Precision healthcare initiatives are increasingly using AI to identify disease risks, predict treatment responses, and improve therapeutic outcomes. The technology is supporting advancements in areas such as oncology, cardiology, neurology, and diagnostics by enabling more accurate and timely medical interventions.

AI-powered healthcare platforms are also contributing to remote care models by supporting virtual healthcare services, remote monitoring, and patient engagement solutions. These capabilities are becoming increasingly important as healthcare systems worldwide focus on improving accessibility and efficiency.

North America Leads AI Healthcare Adoption While Asia Pacific Presents Growth Opportunities

North America continues to represent a significant region for AI healthcare adoption due to advanced healthcare infrastructure, strong technology investments, and increasing implementation of digital health solutions. The region benefits from the presence of leading technology companies, healthcare organizations, and research institutions focused on AI innovation.

Meanwhile, Asia Pacific is expected to witness strong growth opportunities due to increasing healthcare digitalization, rising investments in healthcare technology, improving healthcare infrastructure, and growing demand for advanced medical solutions.

Countries across emerging markets are increasingly exploring AI applications to improve healthcare accessibility, address workforce challenges, and enhance diagnostic capabilities.

Browse more Research Reports in Healthcare IT Industry

Competitive Landscape and Industry Outlook

The global AI in healthcare market includes several prominent technology and healthcare companies focusing on innovation, strategic partnerships, and development of advanced AI platforms. Key companies profiled in the market include Microsoft, IBM, NVIDIA Corporation, Intel Corporation, GE Healthcare, Google, Medtronic, Oracle, Medidata, Merck, and IQVIA.

Market participants are investing in research and development activities, AI-enabled healthcare platforms, cloud-based solutions, and strategic collaborations to strengthen their market position.

As healthcare organizations continue adopting artificial intelligence technologies, AI is expected to play a central role in improving clinical decision-making, operational efficiency, and patient outcomes globally.

Grand View Research Report Coverage

The Grand View Research report provides an in-depth analysis of the artificial intelligence in healthcare market, including market size, growth trends, competitive landscape, segment analysis, and regional insights. The report covers historical data from 2021 to 2025 and provides forecasts for the period from 2026 to 2033.

To learn more about growth opportunities in the AI In Healthcare Market, access the full report from Grand View Research

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Browse GVR’s U.S. Healthcare Facility Mapping & Intelligence Platform

Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter
Blog – https://globalindustryherald.com/

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ai-in-healthcare-market-to-reach-usd-505-6-billion-by-2033–driven-by-rapid-adoption-of-ai-powered-clinical-solutions-and-digital-healthcare-transformation-302808113.html

Technology

Club Offers for Travel Enthusiasts in the U.S.

Published

7 minutes ago

June 24, 2026

NEW YORK, June 24, 2026 /PRNewswire/ — Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, announces a new Club Offer for Club Members in the U.S.

Rigorously vetted and negotiated for us travel enthusiasts:

$899—NEW MEXICO ALL-INCLUSIVE VACATION WITH FLIGHTS
This Riviera Maya resort has been completely transformed. In September, it will debut as a luxurious Kimpton resort. Everything has been refreshed, from the suites to the restaurants and public spaces. This package includes roundtrip flights, 5 nights’ accommodations, airport transfers and all meals and drinks. You can also add additional nights for longer stays. It’s rare to find opening-season rates this low at a brand-new luxury resort, especially when rooms here sell for $400-$600 per night. We’ve negotiated this Club Offer just for us.

Are you a travel enthusiast? Join the club today: https://travelzoo.com

Who are we?
We, Travelzoo®, are the club for travel enthusiasts. We reach 30 million travelers. Club Members receive Club Offers negotiated and rigorously vetted by our deal experts around the globe. Our relationships with thousands of top travel companies give us access to irresistible deals. Our club and its benefits are built around the lifestyle of a modern travel enthusiast.

Media Contact:

Jonathan Jones – New York
jjones@travelzoo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/club-offers-for-travel-enthusiasts-in-the-us-302809648.html

SOURCE Travelzoo

Technology

Royce Micro-Cap Trust (NYSE: RMT) as of May 31, 2026

Published

7 minutes ago

June 24, 2026

NEW YORK, June 24, 2026 /PRNewswire/ —

Average weekly trading volume of approximately 531,385 sharesFund’s adviser has more than 50 years of small- and micro-cap investment experience

CLOSING PRICES AS OF 05/31/26

NAV

15.73

MKT

14.04

AVERAGE ANNUAL TOTAL RETURN AS OF 05/31/26

NAV (%)

MKT (%)

One-Month*

6.21

6.20

Year to Date*

35.72

36.93

One-Year

70.80

73.35

Three-Year

28.50

29.82

Five-Year

11.90

11.99

10-Year

15.25

15.81

*Not Annualized

Important Performance and Expense Information

All performance information reflects past performance, is presented on a total return basis, net of the Fund’s investment advisory fee, and reflects the reinvestment of distributions. Past performance is no guarantee of future results Current performance may be higher or lower than performance quoted. Returns as of the recent month-end may be obtained at www.royceinvest.com. The market price of the Fund’s shares will fluctuate, so that shares may be worth more or less than their original cost when sold.

The Fund normally invests in micro-cap companies, which may involve considerably more risk than investing in larger-cap companies. The Fund’s broadly diversified portfolio does not ensure a profit or guarantee against loss.

PORTFOLIO DIAGNOSTICS

Average Market Cap1

$1070.9M

Weighted Average P/B2

2.3x

Net Assets

$847.4M

Net Leverage

1.5 %

1Geometric Average: This weighted calculation uses each portfolio holding’s market cap in a way designed to not skew the effect of very large or small holdings; instead, it aims to better identify the portfolio’s center, which Royce believes offers a more accurate measure of average market cap than a simple mean or median.

2Harmonic Average: This weighted calculation evaluates a portfolio as if it were a single stock and measures it overall. It compares the total market value of the portfolio to the portfolio’s share in the earnings of its underlying stocks.

The Price-to-Book, or P/B, Ratio is calculated by dividing a company’s share price by its book value per share.

Net leverage is the percentage, in excess of 100 %, of the total value of equity type investments, divided by net assets.

Portfolio Composition

TOP 10 POSITIONS

% OF NET ASSETS (SUBJECT TO CHANGE)

5N Plus

1.8

Cohu

1.5

Ichor Holdings

1.5

NWPX Infrastructure

1.4

Ultra Clean Holdings

1.4

ADTRAN Holdings

1.4

EZCORP Cl. A

1.3

Vishay Precision Group

1.3

Bel Fuse Cl. B

1.3

Graham Corporation

1.3

TOP FIVE SECTORS

% OF NET ASSETS (SUBJECT TO CHANGE)

Industrials

28.4

Information Technology

25.0

Financials

12.8

Health Care

11.9

Consumer Discretionary

10.8

Recent Developments
Royce Micro-Cap Trust, Inc. is a closed-end diversified investment company whose shares of Common Stock (RMT) are listed and traded on the New York Stock Exchange. The Fund’s investment goal is long-term capital growth, which it seeks by investing primarily in equity securities of companies that, at the time of investment, have market capitalization of $1 billion or less.

Daily net asset values (NAVs) for Royce Micro-Cap Trust, Inc. are now available on our website and online through most ticker symbol lookup services and on broker terminals under the symbol XOTCX. For more information, please call The Royce Funds at (800) 221-4268 or visit our website at www.royceinvest.com

An investor in Royce Micro-Cap Trust should consider the Fund’s investment goals, risks, fees, and expenses carefully before investing.

Important Disclosure Information
Closed-End Funds are registered investment companies whose shares of common stock may trade at a discount to their net asset value. Shares of each Fund’s common stock are also subject to the market risks of investing in the underlying portfolio securities held by the Fund. Royce Fund Services, LLC. (“RFS”) is a member of FINRA and has filed this material with FINRA on behalf of each Fund. RFS does not serve as a distributor or as an underwriter to the closed-end funds.

View original content:https://www.prnewswire.com/news-releases/royce-micro-cap-trust-nyse-rmt-as-of-may-31-2026-302809653.html

SOURCE Royce Micro-Cap Trust, Inc.